Targeted Cancer Therapy Using Monoclonal Antibodies
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".
Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 7125
Special Issue Editor
Special Issue Information
Dear Colleagues,
The discovery of murine monoclonal antibodies in 1975, followed by the Nobel prize in medicine in 1984 which was grated to Dr. Georges Koehler and Dr. Cesar Milstein and the enormous development of the field in the following decades, enabled the preparation and production of chimeric, humanized, and human monoclonal antibodies. Although the immune system was developed to protect us from invading pathogens, the first therapeutic monoclonal antibodies, approved by the FDA and EMA, were used to treat cancer. The Nobel prize in medicine was given to Prof. James P. Allison and Prof. Tasuku Honjo in 2018 for the development of immunotherapy, based on monoclonal antibodies, to treat cancer. Monoclonal antibodies (chimeric, humanized, and human) are also very successful in the treatment of autoimmune and dermatological diseases, among others. In the last decade, monoclonal antibodies, mainly human (isolated from patients or produced in transgenic mice), have also been developed to treat infectious diseases such as AIDS and COVID-19. Scientists have provided new technologies to prepare fully human antibodies, based on phage display—Prof. Sir Gregory Winter was awarded the Nobel prize in chemistry in 2018 for his pioneering work on this, for instance. We are still awaiting the first approved drug based on nanobodies (from camelid), and new doors have also opened for new targets for CAR-T therapy and for the preparation of monoclonal antibodies to these targets. All therapeutic monoclonal antibodies can be prepared as ADCs.
In this issue, we will cover the field of targeted cancer therapy using monoclonal antibodies as described above, and authors are encouraged and welcome to provide us with their topics of research (except pure clinical studies). Review articles are also welcome.
Prof. Dr. Vladka Čurin Šerbec
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antibodies
- monoclonal antibodies
- recombinant antibodies
- immunological techniques
- use of antibodies in research, diagnostics, and therapy
